A comparative study of LRRK2, PINK1 and genetically undefined familial Parkinson's disease

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 81, Issue 4, 2010, Pages 391-395

  Nishioka, Kenya ^a   Kefi, Mounir ^b   Jasinska Myga, Barbara ^a,c   Wider, Christian ^a   Vilariño Güell, Carles ^a   Ross, Owen A ^a   Heckman, Michael G ^d   Middleton, Lefkos T ^e   Ishihara Paul, Lianna ^f   Gibson, Rachel A ^f   Amouri, Rim ^b   Yahmed, Samia Ben ^b   Sassi, Samia Ben ^b   Zouari, Mourad ^b   Euch, Ghada El ^b   Farrer, Matthew J ^a   Hentati, Faycal ^b  

^a MAYO GRADUATE SCHOOL   (United States)

^b Institut National de Neurologie Tunisia   (Tunisia)

^c MEDICAL UNIVERSITY OF SILESIA   (Poland)

^d MAYO CLINIC   (United States)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEUCINE RICH REPEAT KINASE 2; PARKIN; PHOSPHOTRANSFERASE; PTEN INDUCED KINASE 1; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DYSKINESIA; DYSTONIA; FEMALE; GENE MUTATION; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; NEUROLOGIC EXAMINATION; ONSET AGE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DEFECT; RATING SCALE; SEX DIFFERENCE; TREMOR; TUNISIA;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; CATCHMENT AREA (HEALTH); FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; POINT MUTATION; PREVALENCE; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; TREMOR; TUNISIA; YOUNG ADULT;

EID: 77950613042     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2009.185231     Document Type: Article

References (23)

1. Farrer MJ. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet 2006;7:306-18.
2. Maraganore DM, de Andrade M, Elbaz A, et al. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA 2006;296:661-70.
3. Ross OA, Wu YR, Lee MC, et al. Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease. Ann Neurol 2008;64:88-92.
4. Di Fonzo A, Wu-Chou YH, Lu CS, et al. A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan. Neurogenetics 2006;7:133-8.
5. Funayama M, Hasegawa K, Kowa H, et al. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol 2002;51:296-301.
6. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004;44:601-7.
7. Paisan-Ruiz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004;44:595-600.
8. Kachergus J, Mata IF, Hulihan M, et al. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 2005;76:672-80.
9. Healy DG, Falchi M, O'Sullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008;7:583-90.
10. Lesage S, Durr A, Tazir M, et al. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J Med 2006;354:422-3.
11. Lesage S, Belarbi S, Troiano A, et al. Is the common LRRK2 G2019S mutation related to dyskinesias in North African Parkinson disease? Neurology 2008;71:1550-2.
12. Hulihan MM, Ishihara-Paul L, Kachergus J, et al. LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study. Lancet Neurol 2008;7:591-4.
13. Lesage S, Ibanez P, Lohmann E, et al. G2019S LRRK2 mutation in French and North African families with Parkinson's disease. Ann Neurol 2005;58:784-7.
14. Ishihara-Paul L, Hulihan MM, Kachergus J, et al. PINK1 mutations and parkinsonism. Neurology 2008;71:896-902.
15. Hughes AJ, Ben-Shlomo Y, Daniel SE, et al. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 1992;42:1142-6.
16. Wider C, Pollo C, Bloch J, et al. Long-term outcome of 50 consecutive Parkinson's disease patients treated with subthalamic deep brain stimulation. Parkinsonism Relat Disord 2008;14:114-9.
17. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22.
18. Linazasoro G. Rate of progression determines the clinical outcome after neural transplantation in Parkinson's disease. Brain 2006;129:E48.
19. Del Sorbo F, Albanese A. Levodopa-induced dyskinesias and their management. J Neurol 2008;255(Suppl 4):32-41.
20. Valente EM, Bentivoglio AR, Dixon PH, et al. Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. Am J Hum Genet 2001;68:895-900.
21. Hatano Y, Sato K, Elibol B, et al. PARK6-linked autosomal recessive early-onset parkinsonism in Asian populations. Neurology 2004;63:1482-5.
22. Bonifati V, Rohe CF, Breedveld GJ, et al. Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. Neurology 2005;65:87-95.
23. Ibanez P, Lesage S, Lohmann E, et al. Mutational analysis of the PINK1 gene in early-onset parkinsonism in Europe and North Africa. Brain 2006;129:686-94.